Migraine is a common neurological syndrome that affects approximately 10–20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the ...
CHATHAM, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and ...
In September 2024, Tonix Medicines launched a national educational campaign focusing on the link between migraine, gastroparesis, and the need for non-oral acute migraine therapies. Tonix ...
[92] Onabotulinum toxin-A is approved for headache prophylaxis in adults with chronic migraine and has approximately the same rate of improvement. Side effects of PAM drugs should be reviewed ...
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...
Tonix announced that the USPTO issued U.S. Patent No. 12,090,139 to the Company, claiming a pharmaceutical composition, a method of treating migraine via intranasal administration, and an ...
CHATHAM, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback